Almirall and BioFocus DPI Announce Collaboration to Find New Hit Compounds Against Key Targets

BARCELONA, Spain & SAFFRON WALDEN, England--(BUSINESS WIRE)--The pharmaceutical company Almirall S.A. and BioFocus, an integrated drug discovery partner, today announced they have entered into a collaboration agreement to find new hit compounds against key targets of interest to Almirall. These compounds will be used to support projects aimed at the treatment of respiratory and inflammatory conditions.

Back to news